EP0752880A4 - Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i - Google Patents

Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i

Info

Publication number
EP0752880A4
EP0752880A4 EP95916183A EP95916183A EP0752880A4 EP 0752880 A4 EP0752880 A4 EP 0752880A4 EP 95916183 A EP95916183 A EP 95916183A EP 95916183 A EP95916183 A EP 95916183A EP 0752880 A4 EP0752880 A4 EP 0752880A4
Authority
EP
European Patent Office
Prior art keywords
treatment
autoimmune diseases
oral tolerance
interferon type
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916183A
Other languages
English (en)
French (fr)
Other versions
EP0752880A1 (de
Inventor
David A Hafler
Howard L Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP0752880A1 publication Critical patent/EP0752880A1/de
Publication of EP0752880A4 publication Critical patent/EP0752880A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
EP95916183A 1994-04-08 1995-04-07 Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i Withdrawn EP0752880A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225372 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
EP0752880A1 EP0752880A1 (de) 1997-01-15
EP0752880A4 true EP0752880A4 (de) 2000-08-09

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916183A Withdrawn EP0752880A4 (de) 1994-04-08 1995-04-07 Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i

Country Status (9)

Country Link
EP (1) EP0752880A4 (de)
JP (1) JPH09511745A (de)
AU (1) AU686797B2 (de)
BR (1) BR9507451A (de)
CA (1) CA2185353A1 (de)
HU (1) HUT74900A (de)
IL (1) IL113303A0 (de)
NO (1) NO964199L (de)
WO (1) WO1995027499A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
BR9509438A (pt) * 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
SI0948358T2 (sl) * 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US20120082644A1 (en) * 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (de) * 1988-01-22 1989-07-26 Collagen Corporation Verfahren zur Unterbindung des Wachstums von normalen Zellen und Krebszellen
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (de) * 1988-01-22 1989-07-26 Collagen Corporation Verfahren zur Unterbindung des Wachstums von normalen Zellen und Krebszellen
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9527499A1 *

Also Published As

Publication number Publication date
JPH09511745A (ja) 1997-11-25
EP0752880A1 (de) 1997-01-15
HUT74900A (en) 1997-02-28
IL113303A0 (en) 1995-07-31
WO1995027499A1 (en) 1995-10-19
HU9602750D0 (en) 1996-11-28
AU2277695A (en) 1995-10-30
NO964199D0 (no) 1996-10-03
CA2185353A1 (en) 1995-10-19
BR9507451A (pt) 1997-08-05
NO964199L (no) 1996-10-03
AU686797B2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
EP0773716A4 (de) Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen
EP0754042A4 (de) Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
EP0831836A4 (de) Synthetische katalytisch freie-radikalfänger zur verwendung als antioxydantien zur vorbeugung und heilung von krankheiten
EP0979074A4 (de) Behandlung oder vorbeugung klimakteriumsymptomen und der osteoporose
EP0921819A4 (de) Krebsbehandlung und -vorbeugung durch gabe von derivaten des menschlichen chorio-gonadotropin
FI973163A7 (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)- desetyylioksibutyniiniä
EP0925046A4 (de) Topische zubereitungen und verfahren zur behandlung von hämorrhoiden
EP0954300A4 (de) Photolthographische strukturerzeugung
BR9305310A (pt) Conjunto de came e conjunto de came "S"
EP0861082A4 (de) Therapie der gewebemembraninsuffizienz
EP0832204A4 (de) Behandlung der insulinresistenz
EP0506893A4 (en) Diagnosis and treatment of diseases
EP0959879A4 (de) Photodynamische therapie zur behandlung von osteosrthritis
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
EP0800396A4 (de) Behandlung hyperandrogener zustände
MA24169A1 (fr) Traitement de l'asthme a l'aide de la tnfr-ig
EP0755255A4 (de) Behandlung der toxoplasmose
EP0866799A4 (de) Apolipoprotein e2 und behandlung der alzheimerschen krankheit
EP0833641A4 (de) Behandlung und vorbeugung von erkrankungen der prostata
EP0679083A4 (de) Prävention und behandlung von sepsis.
FR2765214B1 (fr) Traitement de granulat par un latex anti-desenrobage
EP0981545A4 (de) Behandlung von osteoporose
PL322002A1 (en) Variants of human dnase i
FR2709964B1 (fr) Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès.
FI973259A0 (fi) LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000627

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/17 A, 7A 61K 38/28 B, 7A 61K 38/39 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 38/21 J, 7A 61K 38:26 J, 7A 61K 38:28 J, 7A 61K 38:39 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000915